Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISTH 0036

Drug Profile

ISTH 0036

Alternative Names: ISTH-0036; TGF-Β2 isoform specific antisense oligonucleotide - Isarna Therapeutics

Latest Information Update: 29 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isarna Therapeutics
  • Class Antiglaucomas; Antisense oligonucleotides; Eye disorder therapies
  • Mechanism of Action RNA interference; Transforming growth factor beta2 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scars
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration
  • Phase I Open-angle glaucoma
  • Preclinical Cancer; Dry age-related macular degeneration

Most Recent Events

  • 20 Jul 2023 Preclinical trials in Cancer in Germany (Parenteral) (Isarna Therapeutics pipeline; July 2023)
  • 16 May 2023 ISTH 0036 is still in phase-I clinical trial in Open angle glaucoma in Germany (Intravitreous) (Isarna Therapeutics pipeline, May 2023)
  • 16 May 2023 Preclinical trials in Dry age-related macular degeneration in Germany, prior to May 2023 (unspecified) (Isarna Therapeutics pipeline, May 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top